Hydralazine HCL Tablets, USP, 50 mg in a single blister package, Rx only, Manufactured in Czech R...

FDA Recall #D-1075-2014 — Class II — December 18, 2013

Recall #D-1075-2014 Date: December 18, 2013 Classification: Class II Status: Terminated

Product Description

Hydralazine HCL Tablets, USP, 50 mg in a single blister package, Rx only, Manufactured in Czech Republic by: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0555-89 (carton) and 00182-0555-00 (single blister).

Reason for Recall

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Recalling Firm

Teva Pharmaceuticals USA — Horsham, PA

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

112,800 tablets

Distribution

Nationwide

Code Information

Lot # 6A201018VA; Exp. 01/14.

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated